
SAIL Fusion commenced U.S. commercial launch of its novel BowTie Sacroiliac Fusion System. BowTie is the first SI fusion technology to be based on long-standing, validated joint fusion principles established by the AO foundation and is now the lone commercially available device that integrates both intra‑articular and transfixing components.
MIS BowTie technology and its posterior-inferior surgical technique achieve the AO-based principles of minimal tissue disruption, thorough joint preparation and rigid fixation to enable robust arthrodesis. The device features a novel bowtie shape as well as integrated transfixation and iliac screws to maximize rigidity. It also utilizes a proprietary porous structure and roughened surface technology to facilitate osteointegration.
This launch is part of a limited commercial release that will be expanded in the coming months.
Source: SAIL Fusion
SAIL Fusion commenced U.S. commercial launch of its novel BowTie Sacroiliac Fusion System. BowTie is the first SI fusion technology to be based on long-standing, validated joint fusion principles established by the AO foundation and is now the lone commercially available device that integrates both intra‑articular and transfixing components.
...
SAIL Fusion commenced U.S. commercial launch of its novel BowTie Sacroiliac Fusion System. BowTie is the first SI fusion technology to be based on long-standing, validated joint fusion principles established by the AO foundation and is now the lone commercially available device that integrates both intra‑articular and transfixing components.
MIS BowTie technology and its posterior-inferior surgical technique achieve the AO-based principles of minimal tissue disruption, thorough joint preparation and rigid fixation to enable robust arthrodesis. The device features a novel bowtie shape as well as integrated transfixation and iliac screws to maximize rigidity. It also utilizes a proprietary porous structure and roughened surface technology to facilitate osteointegration.
This launch is part of a limited commercial release that will be expanded in the coming months.
Source: SAIL Fusion
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





